Ser142
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser142  -  TR-beta1 (human)

Site Information
IQKNLHPsYSCkYEG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 449635

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 1 ) , phospho-antibody ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
ERK1 (human) ( 1 ) , ERK2 (human) ( 1 )
Kinases, in vitro:
ERK1 (human) ( 1 ) , ERK2 (human) ( 1 )
Treatments:
levothyroxine sodium ( 1 )

Downstream Regulation
Effects of modification on TR-beta1:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
transcription, altered ( 1 )
Induce interaction with:
p300 (human) ( 1 )
Inhibit interaction with:
SMRT (human) ( 1 )

References 

1

Lin HY, et al. (2003) Identification of the putative MAP kinase docking site in the thyroid hormone receptor-beta1 DNA-binding domain: functional consequences of mutations at the docking site. Biochemistry 42, 7571-9
12809513   Curated Info